The largest prostate cancer screening trial in more than 20 years has expanded to reach Black men, the group at highest risk from the disease. TRANSFORM, a 60-million-pound trial led by Professor Hashim Ahmed at Imperial College London, began recruiting in November 2025 to test new screening methods against the current NHS pathway. The first men have now been tested at a diagnostic centre in Ealing. Stage one will enrol 16,000 men and is expected to finish in December 2027, before a much larger second stage of up to 500,000 men begins in early 2028. In June 2026 the government announced up to 18 million pounds of extra funding so that all eligible Black men can be invited to the second stage. Black men face double the risk of developing and dying from prostate cancer. The UK National Screening Committee decided in June 2026 against population-wide screening, but men aged 45 to 61 with BRCA gene mutations will now be offered screening every two years.
What the Evidence Shows
Prostate cancer is now the most common cancer in Britain, with more than 63,000 men diagnosed each year, over 12,000 deaths, and cases up 42 percent in a decade. Screening is difficult because the PSA blood test produces many false alarms. Cancer Research UK figures show that of 1,000 men screened between the ages of 50 and 60, about 100 have a positive PSA test, 34 go on to have a biopsy, and 28 are diagnosed with cancer, yet only two lives are saved while 20 men are overdiagnosed and 12 receive treatment they do not need. TRANSFORM aims to find a combination of tests that catches aggressive cancers early without that harm, and it has a target that one in ten participants will be Black. If stage one succeeds, screening could begin in as little as two years. Reporting and analysis from sources such as National Institutes of Health track the same developments, and specialists following the TRANSFORM prostate cancer screening trial say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a health system trying to move from treating illness late to preventing it early, against budgets that reward the opposite. Evidence around the TRANSFORM prostate cancer screening trial is being weighed by guideline committees that ask two questions in order: does it work, and can ordinary services actually deliver it at scale. Many good ideas pass the first test and stall on the second.
What Happens Next
What happens next for the TRANSFORM prostate cancer screening trial depends on the slow machinery of guidelines, funding and training catching up with the evidence. Patients asking about it today should expect honest answers that include uncertainty, and clinicians say a service that explains what is not yet known earns more trust than one that oversells. The research pipeline, at least, is moving in the right direction. You can follow related developments in our coverage of health.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.